ethinyl estradiol has been researched along with Hypersensitivity, Type III in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahmed, SA; Cecere, T; Cowan, C; Dai, R; Edwards, MR; Heid, B; Werre, SR | 1 |
| Beaumont, JL; Beaumont, V | 1 |
2 other study(ies) available for ethinyl estradiol and Hypersensitivity, Type III
| Article | Year |
|---|---|
Low-dose 17α-ethinyl estradiol (EE) exposure exacerbates lupus renal disease and modulates immune responses to TLR7/9 agonists in genetically autoimmune-prone mice.
Topics: Animals; Autoantibodies; Blood Urea Nitrogen; Creatinine; Cytokines; Ethinyl Estradiol; Female; Imiquimod; Immune Complex Diseases; Immunoglobulin G; Kidney Glomerulus; Leukocytes; Lupus Nephritis; Membrane Glycoproteins; Mice; Mice, Inbred MRL lpr; Proteinuria; Spleen; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2020 |
[Vascular thrombosis related to oral contraceptives and antiethinylestradiol antibodies--epidemiology and prevention (author's transl)].
Topics: Adult; Antibodies; Contraceptives, Oral; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Humans; Immune Complex Diseases; Thrombosis | 1982 |